BACKGROUND: Identification of genetic risk factors for common diseases, including cancer, highlights the importance of familial risk assessment. Little is known about patterns of familial cancer risk in the general population, or whether this risk is associated with knowledge and use of genetic testing. OBJECTIVE: To examine the distribution of familial cancer risk and its associations with genetic testing in the United States. DESIGN: Cross-sectional analysis of the 2005 National Health Interview Survey (NHIS). PARTICIPANTS: 31,428 adults who completed the NHIS Cancer Control Supplement. MAIN MEASURES: Familial cancer risk was estimated based on the number of first-degree relatives with a breast and ovarian cancer syndrome (BRCA)- or a Lynch-associated cancer, age of onset (<50 or > or = 50 years), and personal history of any cancer. Outcomes included having heard of genetic testing, discussed genetic testing with a physician, been advised by a physician to have testing, and received genetic testing. KEY RESULTS: Most adults (84.5%) had no family history of BRCA- or Lynch syndrome-associated cancer; 12.9% had a single first-degree relative (5.3% with early onset); and 2.7% had > or = 2 first-degree relatives. Although 40.2% of adults had heard of genetic testing for cancer risk, only 5.6% of these individuals had discussed testing with a physician, and of these 36.9% were advised to be tested. Overall, only 1.4% of adults who had heard of genetic testing received a test. Familial risk was associated with higher rates of testing; 49.5% of participants in the highest risk group had heard of testing, of those 14.8% had discussed it with their physician, and 4.5% had received genetic testing. CONCLUSIONS: These nationally representative data provide estimates of the prevalence of familial cancer risk in the US and suggest that information about genetic testing is not reaching many at higher risk of inherited cancer.
BACKGROUND: Identification of genetic risk factors for common diseases, including cancer, highlights the importance of familial risk assessment. Little is known about patterns of familial cancer risk in the general population, or whether this risk is associated with knowledge and use of genetic testing. OBJECTIVE: To examine the distribution of familial cancer risk and its associations with genetic testing in the United States. DESIGN: Cross-sectional analysis of the 2005 National Health Interview Survey (NHIS). PARTICIPANTS: 31,428 adults who completed the NHIS Cancer Control Supplement. MAIN MEASURES: Familial cancer risk was estimated based on the number of first-degree relatives with a breast and ovarian cancer syndrome (BRCA)- or a Lynch-associated cancer, age of onset (<50 or > or = 50 years), and personal history of any cancer. Outcomes included having heard of genetic testing, discussed genetic testing with a physician, been advised by a physician to have testing, and received genetic testing. KEY RESULTS: Most adults (84.5%) had no family history of BRCA- or Lynch syndrome-associated cancer; 12.9% had a single first-degree relative (5.3% with early onset); and 2.7% had > or = 2 first-degree relatives. Although 40.2% of adults had heard of genetic testing for cancer risk, only 5.6% of these individuals had discussed testing with a physician, and of these 36.9% were advised to be tested. Overall, only 1.4% of adults who had heard of genetic testing received a test. Familial risk was associated with higher rates of testing; 49.5% of participants in the highest risk group had heard of testing, of those 14.8% had discussed it with their physician, and 4.5% had received genetic testing. CONCLUSIONS: These nationally representative data provide estimates of the prevalence of familial cancer risk in the US and suggest that information about genetic testing is not reaching many at higher risk of inherited cancer.
Authors: Eugene C Rich; Wylie Burke; Caryl J Heaton; Susanne Haga; Linda Pinsky; M Priscilla Short; Louise Acheson Journal: J Gen Intern Med Date: 2004-03 Impact factor: 5.128
Authors: June C Carroll; Judith Belle Brown; Sean Blaine; Gord Glendon; Patricia Pugh; Wendy Medved Journal: Can Fam Physician Date: 2003-01 Impact factor: 3.275
Authors: Paula W Yoon; Maren T Scheuner; Kris L Peterson-Oehlke; Marta Gwinn; Andrew Faucett; Muin J Khoury Journal: Genet Med Date: 2002 Jul-Aug Impact factor: 8.822
Authors: Heidi A Hamann; Jasmin A Tiro; Joanne M Sanders; Trisha V Melhado; Rachel K Funk; Melissa Y Carpentier; L Kay Bartholomew; Keith E Argenbright; Sally W Vernon Journal: J Cancer Surviv Date: 2013-08-23 Impact factor: 4.442
Authors: Sara J Knight; Ateesha F Mohamed; Deborah A Marshall; Uri Ladabaum; Kathryn A Phillips; Judith M E Walsh Journal: Med Decis Making Date: 2015-01-14 Impact factor: 2.583
Authors: Robert A Bell; Haley McDermott; Tonya L Fancher; Michael J Green; Frank C Day; Michael S Wilkes Journal: J Gen Intern Med Date: 2014-12-02 Impact factor: 5.128
Authors: Jada G Hamilton; Ekland Abdiwahab; Heather M Edwards; Min-Lin Fang; Andrew Jdayani; Erica S Breslau Journal: J Gen Intern Med Date: 2016-12-19 Impact factor: 5.128
Authors: Laura-Mae Baldwin; Katrina F Trivers; C Holly A Andrilla; Barbara Matthews; Jacqueline W Miller; Denise M Lishner; Barbara A Goff Journal: J Gen Intern Med Date: 2014-02-12 Impact factor: 5.128
Authors: Susan T Vadaparampil; Teri L Malo; Kelli M Nam; Alison Nelson; Cara Z de la Cruz; Gwendolyn P Quinn Journal: J Cancer Educ Date: 2014-12 Impact factor: 2.037
Authors: Nicky Dekker; Eleonora B L van Dorst; Rob B van der Luijt; Marielle E van Gijn; Marc van Tuil; Johan A Offerhaus; Margreet G E M Ausems Journal: J Genet Couns Date: 2012-11-30 Impact factor: 2.537